Relay Therapeutics Inc
RLAY8.560USD
-0.090-1.04%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.48BMarket Cap
LossP/E TTM
More Details of Relay Therapeutics Inc Company
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Relay Therapeutics Inc Info
Ticker SymbolRLAY
Company nameRelay Therapeutics Inc
IPO dateJul 16, 2020
CEOPatel (Sanjiv K)
Number of employees261
Security typeOrdinary Share
Fiscal year-endJul 16
Address60 Hampshire Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02139
Phone16173708837
Websitehttps://relaytx.com/
Ticker SymbolRLAY
IPO dateJul 16, 2020
CEOPatel (Sanjiv K)
Company Executives of Relay Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-10.01%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
132.75K
-23.39%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Thomas (Tom) Catinazzo
Mr. Thomas (Tom) Catinazzo
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
--
--
Dr. Claire Mazumdar, Ph.D.
Dr. Claire Mazumdar, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-10.01%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
132.75K
-23.39%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2023
FY2022
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
677.00K
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
SB Investment Advisers (UK) Limited
16.10%
Commodore Capital LP
9.81%
Point72 Asset Management, L.P.
8.52%
Casdin Capital, LLC
6.54%
BlackRock Institutional Trust Company, N.A.
6.05%
Other
52.98%
Shareholders
Shareholders
Proportion
SB Investment Advisers (UK) Limited
16.10%
Commodore Capital LP
9.81%
Point72 Asset Management, L.P.
8.52%
Casdin Capital, LLC
6.54%
BlackRock Institutional Trust Company, N.A.
6.05%
Other
52.98%
Shareholder Types
Shareholders
Proportion
Hedge Fund
36.68%
Investment Advisor
27.26%
Private Equity
16.70%
Investment Advisor/Hedge Fund
13.16%
Research Firm
2.08%
Individual Investor
1.32%
Venture Capital
0.91%
Sovereign Wealth Fund
0.48%
Family Office
0.45%
Other
0.96%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
457
168.31M
97.11%
-38.09M
2025Q2
460
180.78M
105.44%
-7.40M
2025Q1
473
175.15M
102.43%
-21.99M
2024Q4
463
170.97M
101.10%
-14.45M
2024Q3
455
166.81M
103.61%
+17.06M
2024Q2
434
132.20M
98.83%
-25.01M
2024Q1
423
138.51M
105.71%
-7.14M
2023Q4
410
132.38M
103.96%
-10.79M
2023Q3
396
136.20M
110.68%
-5.83M
2023Q2
397
136.32M
112.15%
-5.86M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
SB Investment Advisers (UK) Limited
27.90M
16.19%
--
--
Jun 30, 2025
Commodore Capital LP
13.35M
7.74%
+3.35M
+33.50%
Jun 30, 2025
Point72 Asset Management, L.P.
13.45M
7.8%
+2.62M
+24.19%
Jun 30, 2025
Casdin Capital, LLC
11.40M
6.61%
+2.30M
+25.28%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
10.63M
6.16%
-159.25K
-1.48%
Jun 30, 2025
The Vanguard Group, Inc.
9.35M
5.42%
-2.73M
-22.57%
Jun 30, 2025
Bellevue Asset Management AG
8.23M
4.77%
+853.58K
+11.57%
Jun 30, 2025
Tang Capital Management, LLC
8.07M
4.68%
--
--
Jun 30, 2025
State Street Investment Management (US)
5.20M
3.02%
+43.60K
+0.85%
Jun 30, 2025
Nextech Invest, Ltd.
3.85M
2.23%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.4%
Tema Oncology ETF
0.98%
ALPS Medical Breakthroughs ETF
0.51%
State Street SPDR S&P Biotech ETF
0.33%
ProShares Ultra Nasdaq Biotechnology
0.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
Avantis US Small Cap Equity ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.12%
Invesco RAFI US 1500 Small-Mid ETF
0.09%
iShares Biotechnology ETF
0.08%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.4%
Tema Oncology ETF
Proportion0.98%
ALPS Medical Breakthroughs ETF
Proportion0.51%
State Street SPDR S&P Biotech ETF
Proportion0.33%
ProShares Ultra Nasdaq Biotechnology
Proportion0.17%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.16%
Avantis US Small Cap Equity ETF
Proportion0.14%
Invesco Nasdaq Biotechnology ETF
Proportion0.12%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.09%
iShares Biotechnology ETF
Proportion0.08%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Relay Therapeutics Inc?
The top five shareholders of Relay Therapeutics Inc are:
SB Investment Advisers (UK) Limited holds 27.90M shares, accounting for 16.19% of the total shares.
Commodore Capital LP holds 13.35M shares, accounting for 7.74% of the total shares.
Point72 Asset Management, L.P. holds 13.45M shares, accounting for 7.80% of the total shares.
Casdin Capital, LLC holds 11.40M shares, accounting for 6.61% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 10.63M shares, accounting for 6.16% of the total shares.
SB Investment Advisers (UK) Limited holds 27.90M shares, accounting for 16.19% of the total shares.
Commodore Capital LP holds 13.35M shares, accounting for 7.74% of the total shares.
Point72 Asset Management, L.P. holds 13.45M shares, accounting for 7.80% of the total shares.
Casdin Capital, LLC holds 11.40M shares, accounting for 6.61% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 10.63M shares, accounting for 6.16% of the total shares.
What are the top three shareholder types of Relay Therapeutics Inc?
The top three shareholder types of Relay Therapeutics Inc are:
SB Investment Advisers (UK) Limited
Commodore Capital LP
Point72 Asset Management, L.P.
SB Investment Advisers (UK) Limited
Commodore Capital LP
Point72 Asset Management, L.P.
How many institutions hold shares of Relay Therapeutics Inc (RLAY)?
As of 2025Q3, 457 institutions hold shares of Relay Therapeutics Inc, with a combined market value of approximately 168.31M, accounting for 97.11% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -8.33%.
What is the biggest source of revenue for Relay Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Relay Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
